Eldan and Medicinal Genomics Corp. signed a distribution and sales agreement that covers the full range of Medicinal Genomics’ proprietary cannabis testing platforms for the detection of cannabis genes, genotypes, microorganisms, pests and pathogens on or in cannabis, as well as their full complement of genomics solutions.
“Patient demand in Israel and Europe is big and getting bigger every day. We believe that by making Medicinal Genomics’ products available to these growing markets, we can help provide a safer, more consistent product for those who need it most,” said Moshe Ben-Simon, Head of Eldan’s Life Science’s Division. “We look forward to a long and successful relationship with Medicinal Genomics in Israel and beyond.”
